Materi 78 Sistem Imun Fundamentals And Advances

Published

Table of Contents

The human immune system represents a sophisticated defense network essential for survival, integrating innate and adaptive responses to neutralize pathogens while maintaining self-tolerance. Materi 78 Sistem Imun explores its core mechanisms—from pathogen recognition by pattern recognition receptors to the orchestration of cytokines and antigen-presenting cells—while addressing dysregulation in autoimmune and immunodeficiency disorders. This structured examination spans physiological processes, clinical pathologies, and cutting-edge therapies, including monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors. By dissecting immune responses to infections, aging-related decline, and emerging treatments, the content bridges foundational science with real-world applications in Southeast Asia and beyond.

The outline systematically transitions from fundamental concepts—such as the roles of bone marrow and thymus in lymphocyte maturation—to advanced topics like immunosenescence and vaccine efficacy in elderly populations. Comparative analyses of innate versus adaptive immunity, intracellular versus extracellular pathogen clearance, and regional immunopathologies (e.g., dengue, tuberculosis) provide actionable insights for clinicians, researchers, and students. Interactive elements, including HTML tables and flowcharts, enhance comprehension of complex interactions, while case studies on immunotherapy in oncology and autoimmune modulation underscore its transformative potential.

Materi 78 Sistem Imun

Fundamental Concepts of the Immune System

The human immune system is a complex, highly coordinated network of cells, tissues, and molecules that defends the body against pathogens (e.g., bacteria, viruses, fungi, and parasites) while maintaining tolerance to self-antigens. It operates through two primary branches: innate immunity, a rapid, non-specific first line of defense, and adaptive immunity, a slower but highly specific and memory-driven response. Cellular and molecular components, including leukocytes (white blood cells), cytokines, antibodies, and antigen-presenting cells (APCs), collaborate to detect, neutralize, and eliminate threats while minimizing collateral damage to host tissues. Understanding these mechanisms is critical for comprehending immune system dysfunctions, such as autoimmune diseases, immunodeficiency, and chronic infections.

The immune response begins with pathogen recognition, followed by a cascade of signaling events that activate immune cells. Innate immunity provides immediate but limited specificity, while adaptive immunity tailors responses to unique pathogens through clonal expansion and immunological memory. Key players include natural killer (NK) cells, macrophages, dendritic cells (DCs), neutrophils, T lymphocytes (T cells), and B lymphocytes (B cells), each with distinct roles in pathogen clearance and immune regulation.

Structure and Function of Innate and Adaptive Immunity

The immune system is organized into two interdependent branches: innate immunity and adaptive immunity, each with distinct characteristics, cellular components, and functional mechanisms.

Innate immunity serves as the body’s first line of defense, providing immediate but non-specific responses to pathogens. It relies on pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) to detect pathogen-associated molecular patterns (PAMPs) common to broad classes of microorganisms. Key features include:

  • Rapid response (within minutes to hours).
  • Lack of specificity for individual pathogens.
  • No immunological memory after exposure.
  • Primary cell types: Neutrophils, macrophages, dendritic cells, natural killer (NK) cells, and complement proteins.
  • Adaptive immunity, in contrast, is a highly specialized, pathogen-specific response that develops over days to weeks. It involves clonal selection of lymphocytes (T and B cells) that recognize unique antigens, leading to the production of antibodies (by B cells) and cytotoxic T cells capable of eliminating infected host cells. Key features include:

  • Delayed response (days to weeks).
  • High specificity for individual antigens.
  • Immunological memory enabling faster and stronger responses upon re-exposure.
  • Primary cell types: T helper cells (Th), cytotoxic T cells (Tc), regulatory T cells (Treg), and B cells.
  • The following table compares the critical differences between innate and adaptive immunity:

    Feature Innate Immunity Adaptive Immunity
    Response Time Immediate (minutes to hours) Delayed (days to weeks)
    Specificity Non-specific (recognizes broad pathogen patterns) Highly specific (targets unique antigens)
    Memory Absent Present (long-term immunological memory)
    Primary Cell Types Neutrophils, macrophages, dendritic cells, NK cells, complement proteins T cells (Th, Tc, Treg), B cells, antibodies
    Mechanism of Action Phagocytosis, inflammation, antimicrobial peptides, complement activation Antibody-mediated neutralization, cell-mediated cytotoxicity, cytokine regulation
    Diversity of Receptors Limited (germline-encoded PRRs) Highly diverse (somatic recombination of antigen receptors)
    The interplay between innate and adaptive immunity is essential for effective pathogen clearance. For example, dendritic cells (DCs) act as a bridge by capturing pathogens, processing antigens, and presenting them to T cells via major histocompatibility complex (MHC) molecules, thereby activating adaptive responses.

    Pathogen Recognition and Immune Response Activation

    Pathogen recognition initiates a cascade of immune responses that involve cytokines, antibodies, and antigen-presenting cells (APCs). The process can be broken down into the following stages:

    1. Pathogen Detection
    Innate immune cells, such as macrophages and dendritic cells, recognize pathogens through pattern recognition receptors (PRRs) that bind to pathogen-associated molecular patterns (PAMPs) (e.g., lipopolysaccharides (LPS) in bacteria, double-stranded RNA in viruses). This triggers the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6) and chemokines, which recruit additional immune cells to the site of infection.

    2. Phagocytosis and Antigen Processing
    Phagocytic cells (e.g., macrophages, neutrophils) engulf pathogens via phagocytosis, forming phagosomes that fuse with lysosomes to degrade the pathogen. Dendritic cells process antigens into peptides and present them on MHC molecules for T cell recognition.

    3. Activation of Adaptive Immunity

  • T Cell Activation: Dendritic cells present antigens via MHC class II to CD4+ T helper cells, or via MHC class I to CD8+ cytotoxic T cells. This interaction, along with co-stimulatory signals (e.g., CD80/CD86 binding to CD28), activates T cells.
  • B Cell Activation: T helper cells secrete cytokines (e.g., IL-4, IL-5) that stimulate B cells to proliferate and differentiate into plasma cells (antibody-secreting cells) or memory B cells.
  • 4. Effector Mechanisms

  • Antibody-Mediated Immunity: B cells produce immunoglobulins (IgM, IgG, IgA, etc.) that neutralize pathogens (e.g., by blocking viral entry or opsonizing bacteria for phagocytosis).
  • Cell-Mediated Immunity: Cytotoxic T cells (Tc) recognize MHC class I-presented antigens on infected cells and induce apoptosis via perforin and granzymes. Helper T cells (Th) regulate immune responses through cytokine secretion (e.g., Th1 cells activate macrophages, Th2 cells promote B cell responses).
  • 5. Resolution and Memory
    Once the pathogen is cleared, regulatory mechanisms (e.g., Treg cells, anti-inflammatory cytokines like IL-10 and TGF-β) suppress excessive inflammation. Memory T and B cells persist long-term, enabling faster and more robust responses upon re-exposure (e.g., vaccination).

    Cytokines play a central role in coordinating these responses. For example:

  • IL-12 promotes Th1 differentiation (important for intracellular pathogen clearance).
  • IL-4 drives Th2 differentiation (critical for helminth infections and allergic responses).
  • IFN-γ activates macrophages to enhance phagocytic activity.
  • Primary Lymphoid Organs and Immune Cell Development

    Primary lymphoid organs are the sites where lymphocytes (T and B cells) mature and acquire functional competence. These organs include the bone marrow and thymus, each playing a distinct but critical role in immune cell development.
    The bone marrow is the primary site for hematopoiesis, the process by which stem cells differentiate into all blood cell types, including B cells and myeloid lineage cells (e.g., macrophages, neutrophils). In the bone marrow:
  • Hematopoietic stem cells (HSCs) give rise to common lymphoid progenitors (CLPs), which further differentiate into pro-B cells.
  • B cell development involves V(D)J recombination, a process that generates diverse antibody variable regions to recognize a vast array of antigens. Immature B cells undergo negative selection to eliminate self-reactive clones, ensuring central tolerance (preventing autoimmunity).
  • Natural killer (NK) cells and dendritic cells also originate in the bone marrow before migrating to peripheral tissues.
  • The thymus is the exclusive site for T cell maturation. Here, double-negative (DN) thymocytes (lacking CD4 and CD8) migrate from the bone marrow and undergo:

  • Positive selection: T cells that recognize self-MHC molecules but not self-peptides with high affinity survive, ensuring they can interact
  • Materi 78 Sistem Imun - Ilustrasi 2

    Pathophysiology of Immune Dysregulation

    Immune dysregulation encompasses a spectrum of disorders where the immune system malfunctions, either by overreacting to self-antigens (autoimmunity) or failing to mount an adequate response to pathogens (immunodeficiency). These conditions disrupt immune homeostasis, leading to chronic inflammation, tissue damage, or increased susceptibility to infections. Genetic predispositions, epigenetic modifications, and environmental triggers—such as infections, toxins, or dietary factors—contribute to the breakdown of self-tolerance and immune competence. Understanding these mechanisms is critical for diagnosing, managing, and developing targeted therapies for immune-mediated diseases.

    Mechanisms of Autoimmune Diseases and Failure of Self-Tolerance

    Autoimmune diseases arise from the loss of central or peripheral self-tolerance, where the immune system mistakenly targets host tissues. This process involves genetic susceptibility, environmental triggers, and immune dysregulation, collectively leading to chronic inflammation and tissue destruction.

    Genetic Predisposition

    Autoimmune diseases exhibit strong familial aggregation, with human leukocyte antigen (HLA) polymorphisms (e.g., HLA-DRB1*04 in rheumatoid arthritis, HLA-DR2/3 in systemic lupus erythematosus) conferring the highest risk.
    Key genetic mechanisms include:
  • MHC Class II Molecule Dysregulation: Altered peptide presentation by HLA molecules promotes autoreactive T-cell activation.
  • Polymorphisms in Tolerance Checkpoints: Mutations in genes like CTLA-4 (critical for regulatory T-cell function) or FOXP3 (regulatory T-cell differentiation) impair self-tolerance.
  • Cytokine Gene Variants: Pro-inflammatory cytokines (e.g., TNF-α, IL-6) or anti-inflammatory cytokines (e.g., IL-10) may be dysregulated, skewing immune responses.
  • Environmental Triggers
    Exogenous factors disrupt immune tolerance through molecular mimicry, bystander activation, or epigenetic modifications:

  • Infections: Viral (e.g., Epstein-Barr virus in lupus) or bacterial (e.g., Proteus mirabilis in reactive arthritis) pathogens share epitopes with self-antigens, triggering cross-reactive T/B-cell responses.
  • Toxins and Pollutants: Silica exposure in systemic sclerosis or smoking in rheumatoid arthritis induces citrullination of proteins, generating neoantigens.
  • Diet and Microbiome: Gut dysbiosis (e.g., reduced Faecalibacterium prausnitzii in Crohn’s disease) alters regulatory T-cell populations, while processed foods may promote Th17-mediated autoimmunity.
  • Immune Dysregulation Pathways
    The failure of self-tolerance involves:
    1. Defective Central Tolerance: Thymic negative selection fails to eliminate autoreactive T-cells due to AIRE (Autoimmune Regulator) mutations (seen in APECED syndrome).
    2. Peripheral Tolerance Breakdown:

  • Regulatory T-cell (Treg) Dysfunction: Reduced FOXP3+ Tregs or impaired IDO (indoleamine 2,3-dioxygenase) activity in antigen-presenting cells (APCs) leads to uncontrolled effector T-cell responses.
  • B-cell Hyperactivity: BAFF (B-cell activating factor) overexpression promotes autoreactive B-cell survival, as seen in lupus.
  • 3. Cytokine Imbalance:
  • Th1/Th17 Skewing: Elevated IL-17, IFN-γ, and TNF-α drive tissue damage in rheumatoid arthritis and psoriasis.
  • Type I IFN Signature: In lupus, plasmacytoid dendritic cells (pDCs) overproduce IFN-α in response to nucleic acids, amplifying autoreactive B-cell responses.
  • Example Diseases and Targets

    DiseasePrimary AutoantigenImmune Mechanism
    Rheumatoid ArthritisCitrullinated vimentinTh17/Th1-mediated synovial inflammation
    Systemic Lupus ErythematosusdsDNA, Sm/RNPType I IFN-driven B-cell hyperactivity
    Type 1 DiabetesInsulin/GAD65CD8+ T-cell-mediated β-cell destruction
    Multiple SclerosisMyelin basic protein (MBP)Th1/Th17 CNS inflammation

    Immunodeficiency Disorders: Primary and Secondary Mechanisms

    Immunodeficiencies impair the immune system’s ability to defend against pathogens, categorized into primary (congenital) and secondary (acquired) forms. These disorders disrupt innate or adaptive immunity, leading to recurrent infections, malignancies, or autoimmune complications.

    Primary Immunodeficiencies (PIDs)
    Arise from monogenic defects affecting immune cell development or function. Classification by immune compartment affected:

  • B-cell Deficiencies:
  • X-linked agammaglobulinemia (XLA): BTK gene mutation → blocked B-cell maturation → recurrent bacterial infections (e.g., Streptococcus pneumoniae).
  • Common Variable Immunodeficiency (CVID): Variable ICOS, TACI mutations → hypogammaglobulinemia → sinopulmonary infections, autoimmune diseases.
  • T-cell Deficiencies:
  • Severe Combined Immunodeficiency (SCID): IL2RG, RAG1/2, or ADA mutations → absence of T/B/NK cells → fatal infections by 1 year of age.
  • DiGeorge Syndrome: 22q11.2 deletion → thymic aplasia → T-cell lymphopenia.
  • Combined B/T-cell Deficiencies:
  • Wiskott-Aldrich Syndrome: WASP gene mutation → thrombocytopenia, eczema, and recurrent infections due to defective cytoskeletal function in lymphocytes.
  • Phagocyte Disorders:
  • Chronic Granulomatous Disease (CGD): CYBB (X-linked) or NCF1/2 mutations → defective NADPH oxidase → catalase-positive bacterial/fungal infections (e.g., Aspergillus).
  • Leukocyte Adhesion Deficiency (LAD): ITGB2 mutation → impaired neutrophil migration → delayed separation of umbilical cord, recurrent abscesses.
  • Complement Deficiencies:
  • C3 Deficiency: Impaired opsonization → severe pyogenic infections.
  • C1q/C4 Deficiency: Associated with lupus-like syndromes due to impaired immune complex clearance.
  • Secondary Immunodeficiencies
    Acquired due to external factors disrupting immune function:

  • Infectious Causes:
  • HIV/AIDS: HIV-1 infects CD4+ T-cells via CCR5/CXCR4, leading to:
  • CD4+ T-cell depletion (via pyroptosis or apoptosis).
  • T-cell exhaustion (upregulated PD-1, CTLA-4).
  • B-cell dysfunction (hypogammaglobulinemia, autoantibodies).
  • Malaria: Plasmodium falciparum induces spleen atrophy and regulatory T-cell expansion, increasing susceptibility to Salmonella and Pneumococcus.
  • Iatrogenic Causes:
  • Immunosuppressive Therapies: Chronic corticosteroids or TNF-α inhibitors (e.g., infliximab) increase tuberculosis (TB) and fungal infection risks.
  • Chemotherapy/Radiation: Myelosuppression → neutropenia, bacterial sepsis (e.g., Pseudomonas).
  • Nutritional/Metabolic:
  • Protein-Energy Malnutrition: Reduces IgA, complement, and T-cell proliferation (e.g., kwashiorkor → increased Shigella infections).
  • Zinc Deficiency: Impairs NK-cell activity and Th17 responses (seen in acrodermatitis enteropathica).
  • Aging (Immunosenescence):
  • Thymic involution → reduced naïve T-cells.
  • Inflammaging: Chronic IL-6, TNF-α elevation → increased autoimmunity and infection susceptibility.
  • Clinical Impact by Immune Compartment

    The severity of immunodeficiency correlates with the depth of the defect:
  • T-cell deficiencies → opportunistic infections (e.g., Pneumocystis jirovecii, CMV).
  • B-cell deficiencies → encapsulated bacterial infections (e.g., Haemophilus influenzae).
  • Phagocyte defects → abscesses, mucocutaneous candidiasis.
  • Flowchart: Chronic Inflammation and Autoimmune Progression

    The following textual flowchart outlines the cascade from persistent immune activation to autoimmune tissue damage, incorporating cytokine storms and epigenetic feedback loops:

    1. Initial Trigger

  • [Environmental] Infection (e
  • Immune Response to Infections: Mechanisms of Pathogen Detection and Elimination

    The immune system employs a highly coordinated series of responses to detect, neutralize, and eliminate infectious pathogens, including viruses and bacteria. These processes involve both innate and adaptive immunity, with distinct mechanisms tailored to the pathogen’s location (intracellular vs. extracellular) and nature (e.g., viral replication strategies vs. bacterial toxin production). The timeline of immune activation begins with pattern recognition receptors (PRRs) identifying pathogen-associated molecular patterns (PAMPs), followed by the recruitment of effector cells (e.g., macrophages, neutrophils, NK cells) and the initiation of adaptive immunity via antigen presentation. This section explores the sequential events in viral and bacterial infections, comparative immune strategies, and the role of PRRs in triggering responses, alongside a summary of vaccine mechanisms that leverage these pathways.

    Timeline of Immune Response to Viral and Bacterial Infections

    The immune response to infections follows a phased activation model, where innate immunity provides immediate defense, while adaptive immunity ensures long-term protection. Below is a comparative timeline for intracellular viral infections (e.g., influenza, SARS-CoV-2) and extracellular bacterial infections (e.g., Mycobacterium tuberculosis, Streptococcus pneumoniae), highlighting key differences in cellular recruitment and effector mechanisms.

    Innate Immune Phase (0–48 hours post-infection):
    The initial detection of pathogens relies on germline-encoded PRRs, which recognize conserved microbial structures. For viruses, PRRs such as Toll-like receptors (TLRs) (e.g., TLR3 for dsRNA, TLR7/8 for ssRNA) and RIG-I-like receptors (RLRs) (e.g., RIG-I, MDA5) detect viral nucleic acids in endosomes or cytoplasm, respectively. In bacterial infections, TLRs (e.g., TLR2 for peptidoglycan, TLR4 for LPS) and NOD-like receptors (NLRs) (e.g., NOD2 for bacterial cell wall components) trigger inflammatory cascades.

  • Viral infections:
  • Type I IFN production (IFN-α/β) by infected cells (via TLR3/7 or RLR signaling) induces antiviral states in neighboring cells.
  • Natural killer (NK) cells are activated to lyse infected cells via perforin/granzyme or Fas-FasL pathways.
  • Dendritic cells (DCs) uptake viral antigens and migrate to lymph nodes, presenting peptides via MHC class I to prime CD8+ cytotoxic T cells (CTLs).
  • Bacterial infections:
  • Neutrophils and macrophages are recruited via chemokines (e.g., CXCL8, CCL2) and phagocytose bacteria, releasing reactive oxygen species (ROS) and nitric oxide (NO).
  • Complement activation (via alternative or lectin pathways) opsonizes bacteria (e.g., C3b deposition) for phagocytosis.
  • DCs present bacterial peptides via MHC class II to activate CD4+ helper T cells (Th1/Th17).
  • Adaptive Immune Phase (48–14 days post-infection):
    The adaptive response is pathogen-specific and involves clonal expansion of B and T cells, with distinct strategies for intracellular vs. extracellular pathogens.

    - Viral infections:

  • CD8+ CTLs eliminate infected cells via granule-mediated apoptosis (perforin/granzyme B) or Fas-FasL pathways.
  • CD4+ Th1 cells secrete IFN-γ to activate macrophages and support CTL differentiation.
  • Neutralizing antibodies (IgG, IgA) block viral entry (e.g., anti-SARS-CoV-2 spike antibodies) and facilitate antibody-dependent cellular cytotoxicity (ADCC).
  • Memory formation: Long-lived central memory T cells (TCM) and plasma cells ensure rapid recall responses.
  • - Bacterial infections:

  • Th1 cells activate macrophages via IFN-γ to kill intracellular bacteria (e.g., M. tuberculosis).
  • Th17 cells recruit neutrophils via IL-17 to combat extracellular bacteria (e.g., S. pneumoniae).
  • Opsonizing antibodies (IgG1/3, IgA) enhance phagocytosis (e.g., anti-pneumococcal capsule antibodies).
  • Memory formation: Effector memory T cells (TEM) and long-lived plasma cells provide durable protection.
  • Resolution Phase (14+ days post-infection):

  • Regulatory T cells (Treg) and anti-inflammatory cytokines (IL-10, TGF-β) limit tissue damage.
  • Apoptosis of activated lymphocytes via Fas-FasL or PD-1/PD-L1 pathways prevents autoimmunity.
  • Immunological memory ensures faster responses upon re-exposure (e.g., annual influenza vaccines).
  • Comparative Analysis: Immune Responses to Intracellular vs. Extracellular Pathogens

    The immune system employs pathogen-specific strategies that reflect the location and replication cycle of the invader. Below is a comparative breakdown of key differences in antibody classes, T-cell involvement, and memory formation.
    FeatureIntracellular Pathogens (Viruses)Extracellular Pathogens (Bacteria)
    Primary PRRsTLR3 (dsRNA), TLR7/8 (ssRNA), RLRs (RIG-I/MDA5), cGAS-STING (DNA)TLR2/4/5 (peptidoglycan, LPS, flagellin), NLRs (NOD1/2)
    Key Innate EffectorsType I IFN (IFN-α/β), NK cells, CTLs (via MHC I)Neutrophils, macrophages, complement (C3a/C5a)
    Adaptive Antibody ResponseNeutralizing IgG/IgA (blocks entry), ADCC (IgG)Opsonizing IgG1/3/IgA (enhances phagocytosis)
    T-Cell DominanceCD8+ CTLs (MHC I-restricted), Th1 (IFN-γ for macrophages)Th1/Th17 (IFN-γ/IL-17 for macrophage/neutrophil activation)
    Memory FormationTCM (lymphoid tissues), plasma cells (bone marrow)TEM (mucosal/tissue surveillance)
    Vaccine StrategyLive-attenuated (MMR), mRNA (COVID-19), viral vectors (Ebola)Subunit (pneumococcal conjugate), toxoid (tetanus)
    Example PathogensInfluenza, SARS-CoV-2, HIVS. pneumoniae, M. tuberculosis, Vibrio cholerae
    Key Differences:
  • Antibody Function: Viral infections prioritize neutralization (preventing cell entry), while bacterial infections rely on opsonization (enhancing phagocytosis).
  • T-Cell Polarization: Viruses induce CTL-dominant responses, whereas bacteria trigger Th1/Th17 responses depending on intracellular vs. extracellular niches.
  • Memory Localization: Viral memory is systemic (TCM in lymph nodes), while bacterial memory is mucosal/tissue-resident (TEM).
  • Role of Pattern Recognition Receptors (PRRs) in Initiating Immune Responses

    PRRs are evolutionarily conserved receptors that recognize pathogen-associated molecular patterns (PAMPs) to trigger innate immunity. Their ligand specificity dictates the type of immune response, with distinct PRR families mediating recognition of viral vs. bacterial components.

    Major PRR Families and Their Ligands:

    Toll-Like Receptors (TLRs):
    Detect microbial motifs in endosomes (TLR3,7,8,9) or cell surface (TLR1/2,4,5,6).
  • TLR3: Binds dsRNA (viral replication intermediate).
  • TLR7/8: Recognizes ssRNA (e.g., influenza, SARS-CoV-2).
  • TLR4: Detects LPS (Gram-negative bacteria, e.g., E. coli).
  • TLR2: Binds peptidoglycan (Gram-positive bacteria, e.g., S. pneumoniae).
  • NOD-Like Receptors (NLRs):
    Cytosolic sensors for bacterial cell wall components

    Materi 78 Sistem Imun - Ilustrasi 3

    Immunotherapy and Emerging Treatments in Modern Medicine

    Immunotherapy represents a paradigm shift in medical treatment, leveraging the body’s immune system to target diseases with precision. Unlike traditional therapies that broadly suppress immune function or attack cells indiscriminately, immunotherapy exploits specific immune pathways—such as monoclonal antibodies, genetically engineered cells, and checkpoint inhibitors—to achieve targeted effects. These advancements have revolutionized oncology, autoimmune disease management, and infectious disease control, offering durable responses where conventional treatments fail.

    The development of immunotherapy is underpinned by molecular biology, immunology, and bioengineering, enabling therapies that modulate immune activation or suppression with minimal off-target toxicity. Below, the focus lies on monoclonal antibodies, CAR-T cell therapy, immune checkpoint inhibitors, and their applications in autoimmune diseases, highlighting mechanisms, clinical outcomes, and challenges.

    Monoclonal Antibodies: Mechanisms of Action and Clinical Applications

    Monoclonal antibodies (mAbs) are laboratory-produced proteins designed to bind with high specificity to antigens on pathogens, cancer cells, or immune regulators. Their therapeutic efficacy stems from three primary mechanisms: neutralization (blocking pathogen receptors or growth factors), opsonization (tagging cells for phagocytosis), and immune modulation (activating or inhibiting immune cells). Examples like rituximab (anti-CD20) and trastuzumab (anti-HER2) exemplify these principles in oncology and autoimmune diseases.

    Rituximab (Anti-CD20)

  • Mechanism: Binds to the CD20 antigen on pre-B and mature B cells, triggering complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis.
  • Applications: Approved for B-cell lymphomas (e.g., non-Hodgkin lymphoma) and rheumatoid arthritis (RA) by depleting autoreactive B cells.
  • Side Effects: Infusion reactions (fever, chills), increased infection risk (due to B-cell depletion), and progressive multifocal leukoencephalopathy (PML) in rare cases.
  • Trastuzumab (Anti-HER2)

  • Mechanism: Targets the human epidermal growth factor receptor 2 (HER2), inhibiting tumor cell proliferation and recruiting immune effector cells via ADCC.
  • Applications: Standard treatment for HER2-positive breast and gastric cancers in combination with chemotherapy.
  • Side Effects: Cardiac dysfunction (due to HER2’s role in cardiomyocyte signaling), infusion-related reactions, and interstitial lung disease (ILD).
  • Emerging mAbs in Autoimmunity

  • Secukinumab (Anti-IL-17A): Used in psoriasis and psoriatic arthritis by blocking pro-inflammatory cytokine IL-17, reducing skin and joint inflammation without broad immunosuppression.
  • Inebilizumab (Anti-CD19): Approved for neuromyelitis optica spectrum disorder (NMOSD) by depleting pathogenic B cells, demonstrating targeted autoimmunity modulation.
  • CAR-T Cell Therapy: Genetic Engineering and Clinical Challenges

    Chimeric antigen receptor (CAR)-T cell therapy involves extracting a patient’s T cells, genetically modifying them to express receptors targeting tumor antigens (e.g., CD19), and reinfusing them to induce sustained antitumor responses. This personalized cellular therapy has achieved unprecedented remission rates in relapsed/refractory hematological malignancies, particularly B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL).

    Genetic Engineering Process
    1. Leukapheresis: Collection of peripheral blood mononuclear cells (PBMCs) from the patient.
    2. T-Cell Isolation: CD3+ T cells are purified and activated ex vivo with anti-CD3/CD28 beads.
    3. Transduction: Lentiviral or retroviral vectors introduce the CAR construct (comprising an extracellular antigen-binding domain, a hinge, a transmembrane domain, and intracellular costimulatory domains like 4-1BB or CD28).
    4. Expansion and Quality Control: Modified T cells are expanded and tested for viability, CAR expression, and sterility.
    5. Reinfusion: Lymphodepleting chemotherapy (e.g., fludarabine/cyclophosphamide) precedes CAR-T infusion to reduce regulatory T cells and enhance engraftment.

    Clinical Efficacy and Challenges

  • Efficacy: CD19-CAR-T (e.g., tisagenlecleucel, axicabtagene ciloleucel) achieves 80–90% complete remission (CR) in relapsed B-ALL and 40–60% CR in DLBCL, with some patients maintaining responses for 5+ years.
  • Cytokine Release Syndrome (CRS): A systemic hyperinflammatory response (fever, hypotension, multiorgan failure) triggered by CAR-T activation, managed with tocilizumab (anti-IL-6R) and steroids.
  • Neurotoxicity: Immune effector cell-associated neurotoxicity syndrome (ICANS) (e.g., encephalopathy, seizures) linked to CAR-T trafficking to the CNS; risk factors include high tumor burden and CRS severity.
  • Relapse Mechanisms: Antigen escape (e.g., CD19-negative variants) or T-cell exhaustion; dual-target CARs (CD19 + CD22) are under investigation to mitigate this.
  • Case Study: Kymriah (Tisagenlecleucel) in Pediatric B-ALL

  • Trial Data: 82% event-free survival (EFS) at 12 months in relapsed/refractory pediatric B-ALL (NCT02435849), compared to 15% with standard chemotherapy.
  • Limitations: High cost (~$475,000 per treatment), limited access in low-resource settings, and long-term risks (e.g., secondary malignancies from insertional mutagenesis in early viral vector designs).
  • Immune Checkpoint Inhibitors: Mechanisms and Oncological Applications

    Immune checkpoint inhibitors (ICIs) disrupt negative regulatory pathways that suppress T-cell activation, restoring antitumor immunity. The programmed cell death protein 1 (PD-1) and its ligand PD-L1, as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), are primary targets. By blocking these checkpoints, ICIs enhance T-cell proliferation and cytokine production, enabling immune-mediated tumor destruction.

    Key Checkpoint Pathways

    CheckpointMechanismTherapeutic AgentsApproved Indications
    PD-1Inhibits T-cell activation upon binding PD-L1 (expressed by tumors/APCs).Pembrolizumab, Nivolumab, CemiplimabMelanoma, NSCLC, RCC, Hodgkin lymphoma
    PD-L1Ligand for PD-1; upregulated in tumors to evade immunity.Atezolizumab, Avelumab, DurvalumabBladder cancer, NSCLC, HCC, MSI-H colorectal
    CTLA-4Outcompetes CD28 for B7 ligands, suppressing T-cell priming in lymph nodes.Ipilimumab, TremelimumabMelanoma, RCC, MSI-H colorectal
    Mechanisms of Action
    1. PD-1/PD-L1 Blockade: Prevents tumor-mediated T-cell exhaustion, enhancing intratumoral CD8+ T-cell infiltration and IFN-γ production.
    2. CTLA-4 Blockade: Disrupts early T-cell activation in lymph nodes, increasing naïve T-cell priming and memory T-cell generation.

    Clinical Outcomes in Solid Tumors

  • Melanoma: Ipilimumab (CTLA-4) improved 5-year survival to 26% in metastatic melanoma (vs. 13% with chemotherapy), while Nivolumab + Ipilimumab achieved 60% 5-year OS in CheckMate 067.
  • Non-Small Cell Lung Cancer (NSCLC): Pembrolizumab (PD-1) in PD-L1-high tumors showed 40% 5-year OS (vs. 15% with chemotherapy) in KEYNOTE-001.
  • Renal Cell Carcinoma (RCC): Nivolumab + Ipilimumab yielded 42% 2-year OS in CheckMate 214, surpassing sunitinib (30%).
  • Challenges and Resistance

  • Primary Resistance: Low mutational burden (TMB) or immune-desert tumors (e.g., pancreatic cancer) lack neoantigens for T-cell recognition.
  • Acquired Resistance: Upregulation of alternative checkpoints (e.g., TIGIT, LAG-3) or loss of MHC-I in tumor cells.
  • Toxicities: Immune-related adverse events (irAEs) (e
  • Immune System in Aging and Lifespan (Immunosenescence and Aging)

    Aging fundamentally alters immune system functionality, a phenomenon termed immunosenescence, characterized by progressive deterioration in immune competence and increased susceptibility to infections, chronic diseases, and reduced vaccine efficacy. This decline stems from intrinsic cellular aging, hormonal shifts, and persistent low-grade inflammation (inflammaging), which collectively impair adaptive and innate immune responses. Understanding these changes is critical for developing targeted interventions to enhance immune resilience in the elderly, a population disproportionately affected by age-related pathologies.

    The immune system undergoes systemic reorganization with age, marked by thymic atrophy, diminished naive lymphocyte production, and skewed cytokine profiles favoring pro-inflammatory states. These alterations underlie the heightened vulnerability of older adults to infections, autoimmune disorders, and malignancies. Below, the physiological mechanisms of immunosenescence are examined, alongside its clinical manifestations in vaccine responses and comparative immune profiles between young and elderly individuals.

    Physiological Mechanisms of Immunosenescence

    Immunosenescence arises from a convergence of developmental, cellular, and systemic changes that collectively weaken immune surveillance and adaptive immunity.

    Thymic involution and reduced naive T-cell output
    The thymus, responsible for T-cell maturation, undergoes involution beginning in early adulthood, with near-complete replacement by fatty tissue by age 70. This process reduces the repertoire diversity of naive T-cells, as thymic output declines from ~10^7 cells/day in youth to negligible levels in the elderly. Consequently, T-cell receptor (TCR) diversity narrows, impairing the ability to recognize novel antigens. The reliance on memory T-cells (expanded via homeostatic proliferation) increases susceptibility to infections by unfamiliar pathogens, while T-cell exhaustion (marked by upregulation of PD-1, Tim-3) further compromises functionality.

    Altered innate immunity and inflammaging
    Innate immune cells, including macrophages, neutrophils, and NK cells, exhibit reduced phagocytic and cytotoxic activity with age. Concurrently, chronic low-grade inflammation (inflammaging) emerges due to:

  • Accumulation of senescent cells (e.g., in adipose tissue, vasculature) secreting pro-inflammatory cytokines (IL-1β, IL-6, TNF-α).
  • Dysregulated autophagy in myeloid cells, impairing pathogen clearance.
  • Epigenetic drift in immune cells, altering gene expression profiles toward a pro-inflammatory state.
  • Cytokine milieu shifts
    Aging skews cytokine production toward a Th2/Th17-dominant profile, with reduced Th1 (IFN-γ, IL-2) and Tfh (IL-21) responses critical for viral clearance and antibody affinity maturation. Dendritic cells (DCs) also exhibit impaired cross-presentation, further limiting CD8+ T-cell priming.

    Impact on Vaccine Efficacy in the Elderly

    Vaccination in older adults is compromised by quantitative and qualitative deficits in immune responses, leading to reduced protection against influenza, pneumococcus, and SARS-CoV-2.

    Reduced antibody responses

  • Lower vaccine-induced antibody titers: Elderly individuals mount 2–10-fold weaker neutralizing antibody responses to influenza and COVID-19 vaccines compared to young adults.
  • Poorer antibody affinity: Somatic hypermutation in B-cells is less efficient, yielding antibodies with lower avidity and shorter-lived plasma cell survival.
  • Impaired germinal center reactions: Follicular helper T-cells (Tfh) decline with age, reducing B-cell class-switching and memory B-cell generation.
  • T-cell dysfunction in vaccine responses

  • Diminished CD4+ T-cell help: Th1 responses (critical for influenza and COVID-19 vaccines) are attenuated, with reduced IL-2 and IFN-γ production.
  • Altered CD8+ T-cell memory: Memory CD8+ T-cells in the elderly exhibit premature senescence and reduced polyfunctionality (e.g., lower co-production of IFN-γ, TNF-α, and IL-2).
  • Strategies to enhance vaccine efficacy

  • Adjuvant-enhanced vaccines: Adjuvants like AS03 (influenza) or alum (COVID-19) can partially restore Th1 responses.
  • Higher antigen doses: Increased vaccine dosages (e.g., high-dose influenza vaccine) improve antibody titers.
  • Prime-boost strategies: Sequential vaccination (e.g., mRNA followed by protein subunit) can overcome immunosenescence-induced deficits.
  • Targeting inflammaging: Senolytics (e.g., dasatinib + quercetin) or anti-IL-6/IL-1β therapies may reduce chronic inflammation and improve vaccine responses.
  • Epigenetic reprogramming: NAMPT inhibitors or HDAC modulators are under investigation to rejuvenate immune cells.
  • Comparative Immune Profiles: Young vs. Elderly During Infection

    The immune response to infection diverges markedly between young and elderly individuals, reflecting qualitative and quantitative deficits in aging.

    Innate immune differences

    ParameterYoung AdultsElderly Individuals
    Neutrophil functionRapid chemotaxis, ROS production, NETosisImpaired migration, reduced phagocytosis, delayed apoptosis
    NK cell activityStrong IFN-γ and perforin-mediated killingReduced cytotoxicity, altered cytokine profile (↓IFN-γ, ↑IL-10)
    Macrophage polarizationBalanced M1/M2 responsesSkewed toward M2 (pro-resolution), impaired M1 activation
    Adaptive immune disparities
  • Antibody responses:
  • Young: Rapid IgM→IgG class-switching, high-affinity antibodies, long-lived plasma cells.
  • Elderly: Delayed IgG subclass switching (↓IgG2, ↑IgG4), lower affinity antibodies, shorter-lived plasma cells.
  • T-cell functionality:
  • Young: Robust Th1/Th2 balance, polyfunctional CD8+ T-cells (IFN-γ+, TNF-α+, IL-2+).
  • Elderly: Th1 bias loss, CD8+ T-cells exhibit exhaustion markers (PD-1, Tim-3), reduced proliferation, and telomere attrition.
  • Cytokine storm risk:
  • Young: Controlled pro-inflammatory responses (e.g., IFN-I, TNF-α).
  • Elderly: Exaggerated inflammaging-driven responses, increasing sepsis and ARDS risk.
  • Pathogen-specific examples

  • Influenza: Elderly individuals exhibit delayed viral clearance, prolonged shedding, and higher hospitalization rates due to impaired CD8+ T-cell and antibody responses.
  • SARS-CoV-2: Reduced neutralizing antibody titers, lower T-cell cross-reactivity to spike protein variants, and higher cytokine storm risk (e.g., ↑IL-6, ↑IL-1β).
  • Age-Associated Diseases Linked to Chronic Inflammation and Immune Dysfunction

    Persistent low-grade inflammation (inflammaging) and immune dysregulation contribute to multiple age-related pathologies, with potential therapeutic targets emerging in immunogerontology.
    Disease Immune Dysfunction Mechanism Key Biomarkers Therapeutic Targets
    Alzheimer’s Disease (AD)
    • Microglial dysfunction: Chronic activation (M1 polarization) → amyloid-β (Aβ) phagocytosis impairment.
    • Neuroinflammation: TNF-α, IL-1β, and IL-6 promote synaptic loss and tau phosphorylation.
    • T-cell infiltration: Th1/Th17 cells contribute to blood-brain barrier (BBB) disruption.
    • ↑ CSF IL-1β, TNF-α, IL-6
    • ↑ Plasma p-tau181, Aβ42/40 ratio
    • ↑ Microglial activation (CD68+, HLA-DR+)
    • Anti-inflammatory: Minocycline (microglial M2 shift), canakinumab (IL-1β

      Materi 78 Sistem Imun synthesizes a comprehensive framework of immunology, revealing how disruptions in immune regulation underpin diseases from rheumatoid arthritis to HIV/AIDS, while innovations like CAR-T therapy and checkpoint inhibitors redefine treatment paradigms. The interplay between aging, inflammation, and vaccine responsiveness highlights critical gaps in geriatric care, urging tailored interventions to restore immune competence. By integrating mechanistic details with global health challenges—such as dengue coinfections and tuberculosis—this resource equips stakeholders to navigate both theoretical and applied dimensions of immunology. The future of immunotherapy, shaped by precision medicine and regional epidemiological data, promises to reshape diagnostics, therapeutics, and public health strategies worldwide.